Cardiotoxicity: Anthracyclines and long term cancer survivors

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 1326-1328

  Patanè, Salvatore ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

Anthracyclines; Cancer chemotherapy; Cardio oncology; Cardiotoxicity

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

CARDIOTOXICITY; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; HUMAN; NEOPLASMS; SURVIVOR;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; SURVIVORS;

EID: 84908253610     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.149     Document Type: Article

References (71)

1. E. Conti, A. Romiti, and M.B. Musumeci Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors Int J Cardiol 167 6 Sep. 10 2013 2421 2429
2. S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, and M. Nicolae Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int J Cardiol 172 2 Mar 15 2014 e331 e333
3. S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, and Y. Kihara Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients Int J Cardiol 167 5 Sep. 1 2013 2335 2337
4. J.M. Scott, L.W. Jones, and W.E. Hornsby Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training Int J Cardiol 171 2 Feb. 1 2014 e50 e51
5. S. Claridge, A. Chakrabarti, K. Greaves, and C.J. Boos Successful use of trastuzumab following cardiac resynchronisation therapy Int J Cardiol 166 2 Jun. 20 2013 e33 e34
6. M. Lotrionte, G. Palazzoni, and A. Abbate Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue doppler imaging Evaluation) randomized pilot study Int J Cardiol 167 3 Aug. 10 2013 1055 1057
7. M.G. Kaya, M. Ozkan, and O. Gunebakmaz Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 167 5 Sep. 1 2013 2306 2310
8. Y. Ozkanlar, M.S. Aktas, and M. Turkeli Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity Int J Cardiol 173 3 May 15 2014 519 521
9. Y.F. Hu, C.J. Liu, and P.M. Chang Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients Int J Cardiol 165 2 May 10 2013 355 357
10. A. Budaj-Fidecka, M. Kurzyna, and A. Fijałkowska ZATPOL registry investigators. In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL registry data Int J Cardiol 168 4 Oct. 9 2013 3543 3549
11. P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, and S. Patanè Contrast-enhancing right atrial thrombus in cancer patient Int J Cardiol 173 3 May 15 2014 e35 e37
12. S. Grover, D.P. Leong, and A. Chakrabarty Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers Int J Cardiol 168 6 Oct. 15 2013 5465 5467
13. W. Jurczak, S. Szmit, and M. Sobociński Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study Int J Cardiol 168 6 Oct. 15 2013 5212 5217
14. C. Lestuzzi Cardioncology, oncocardiology. Are we barking up the wrong tree? Int J Cardiol 167 2 Jul. 31 2013 307 309
15. P. Pugliatti, R. Donato, C. Zito, S. Carerj, and S. Patanè Cardio inhibitory vasovagal syncope in a cancer patient Int J Cardiol 174 2 Jun 15 2014 e64 e65
16. P. Pugliatti, C. De Gregorio, and S. Patanè The chance finding of echocardiographic complications of infective endocarditis Int J Cardiol 161 3 Nov. 29 2012 e50 e51
17. S. Patanè Breast cancer treatment cardioprotective strategies: the King is naked J Am Heart Assoc. 2014 Published July 22, 2014 http://www.jaha.ahajournals.org/content/3/2/e000665/reply
18. Y. Elkina, S. Palus, and A. Tschirner Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia Int J Cardiol 170 2 Dec. 10 2013 160 166
19. J. Springer, A. Tschirner, K. Hartman, S. von Haehling, S.D. Anker, and W. Doehner The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy Int J Cardiol 168 4 Oct. 9 2013 3527 3531
20. S. Palus, S. von Haehling, and V.C. Flach Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia Int J Cardiol 168 4 Oct. 9 2013 3412 3418
21. V. Avbelj, and R. Trobec A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope Int J Cardiol 166 3 Jul. 1 2013 e59 e61
22. W.J. Jang, H.R. Yim, S.H. Lee, S.J. Park, J.S. Kim, and Y.K. On Prognosis after tilt training in patients with recurrent vasovagal syncope Int J Cardiol 168 4 Oct. 9 2013 4264 4265
23. K.P. Loh, and O. Ogunneye Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! Int J Cardiol 164 3 Apr. 15 2013 e38 e39
24. S. Patanè, and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur Heart J 30 10 May 2009 1169 1170
25. M. Arcopinto, C.A. Cella, and R. Wesolowski Primary prevention of cancer-related thrombosis: special focus on ambulatory patients Int J Cardiol 173 3 May 15 2014 583 584
26. S. Patanè Cancer Multidrug Resistance -Targeted therapy in both cancer and cardiovascular system with cardiovascular drugs. Int J Cardiol Aug 2 2014 10.1016/j.ijcard.2014.07.158
27. S. Patanè ERBB1/ EGFR and ERBB2 (HER2/neu) - Targeted therapies in cancer and cardiovascular system with cardiovascular drugs Int J Cardiol Aug 2 2014 10.1016/j.ijcard.2014.07.161
28. S. Patanè, and F. Marte Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol 146 1 Jan. 7 2011 e20 e22
29. S. Patanè, and F. Marte Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario Int J Cardiol 134 3 May 29 2009 e147 e149
30. S. Patanè Prostate-specific antigen kallikrein and the heart World J Cardiol 1 1 Dec. 31 2009 23 25
31. G.M. Calvagna, and S. Patanè Transvenous pacemaker lead extraction in infective endocarditis Int J Cardiol 176 2 Jul 12 2014 511 513
32. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res 7 3 Apr. 2014 369 371
33. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy? J Cardiovasc Transl Res 7 3 Apr. 2014 372 374
34. S. Patanè A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis Int J Cardiol 157 3 Jun. 14 2012 448 449
35. S. Patanè Cardiotoxicity: Cisplatin and long term cancer survivors Int J Cardiol 175 1 Jul 15 2014 201 202
36. S. Patanè A challenge in cardiology: the oncosurgery Int J Cardiol 174 2 Jun 15 2014 411 412
37. S. Patanè Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer Curr Med Res Opin 26 Jun 2014 1 2 http://informahealthcare.com
38. S. Patanè, F. Marte, M. Sturiale, and G. Dattilo ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses Int J Cardiol 148 2 Apr. 14 2011 e31 e33
39. M. Scarano, F. Pezzuoli, G. Torrisi, G.M. Calvagna, and S. Patanè Cardiovascular implantable electronic device infective endocarditis Int J Cardiol 173 3 May 15 2014 e38 e39
40. K.L. Wang, C.J. Liu, and T.F. Chao Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis Int J Cardiol 167 5 Sep. 1 2013 2162 2166
41. B. Ky, P. Vejpongsa, E.T. Yeh, T. Force, and J.J. Moslehi Emerging paradigms in cardiomyopathies associated with cancer therapies Circ Res 113 6 Aug. 30 2013 754 764 [Review]
42. S. Patanè Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies J Card Fail 20 6 Jun 2014 456 457
43. S. Patanè HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs Int J Cardiol Aug 2 2014 10.1016/j.ijcard.2014.07.129
44. T.M. Suter, and M.S. Ewer Cancer drugs and the heart: importance and management Eur Heart J 34 15 2013 1102 1111
45. M. Mazevet, M. Moulin, and A. Llach-Martinez Complications of chemotherapy, a basic science update Presse Med 42 9 Pt 2 2013 e352 e361
46. M. Hoiczyk, K. Iliodromitis, and S. Bauer Intimal sarcoma of the pulmonary artery with unusual findings: a case report Clin Res Cardiol 101 5 2012 397 401
47. S.E. Lipshultz, R. Karnik, P. Sambatakos, V.I. Franco, S.W. Ross, and T.L. Miller Anthracycline-related cardiotoxicity in childhood cancer survivors Curr Opin Cardiol 29 1 2014 103 112
48. C.A. Geisberg, and D.B. Sawyer Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage Curr Hypertens Rep 12 6 2010 404 410
49. J.M. Goldberg, R.E. Scully, S.E. Sallan, and S.E. Lipshultz Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia J Pediatr Hematol Oncol 34 5 2012 395 397
50. R.M. Steingart, N. Yadav, C. Manrique, J.R. Carver, and J. Liu Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management Semin Oncol 40 6 2014 690 708
51. S.H. Giordano, Y.F. Kuo, J.L. Freeman, T.A. Buchholz, and G.N. Hortobagyi Goodwin JS Risk of cardiac death after adjuvant radiotherapy for breast cancer J Natl Cancer Inst 97 6 2005 419 424
52. C. Faure-Conter, N. Rocourt, and H. Sudour-Bonnange Pediatric germ cell tumours Bull Cancer 100 4 2013 381 391
53. T. Tamura, A. Kuwahara, and M. Yamamori VEGF-634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma Int J Med Sci 9 10 2012 833 837
54. C. Kreatsoulas, S.S. Anand, and S.V. Subramanian An emerging double burden of disease: the prevalence of individuals with cardiovascular disease and cancer J Intern Med 275 5 May 2014 494 505
55. A. Ascensão, P.J. Oliveira, and J. Magalhães Exercise as a beneficial adjunct therapy during Doxorubicin treatment - role of mitochondria in cardioprotection Int J Cardiol 156 1 Apr. 5 2012 4 10 [Review]
56. K. Kalam, and T.H. Marwick Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis Eur J Cancer 49 13 2013 2900 2909
57. A. Cascales, B. Sánchez-Vega, and N. Navarro Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation Int J Cardiol 154 3 Feb. 9 2012 282 286
58. W.Y. Cheung, R. Levin, and S. Setoguchi Appropriateness of cardiovascular care in elderly adult cancer survivors Med Oncol 30 2 2013 561
59. M. Ammon, N. Arenja, and G. Leibundgut Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice J Card Fail 19 9 2013 629 634
60. P. Menna, O.G. Paz, M. Chello, E. Covino, E. Salvatorelli, and G. Minotti Anthracycline cardiotoxicity Expert Opin Drug Saf 11 Suppl. 1 2012 S21 S36
61. M.L. Luoma, L. Hakamies-Blomqvist, C. Blomqvist, R. Nikander, M. Gustavsson-Lilius, and T. Saarto Experiences of breast cancer survivors participating in a tailored exercise intervention - a qualitative study Anticancer Res 34 3 2014 1193 1199
62. L.M. Budden, B.A. Hayes, and P.G. Buettner Women's decision satisfaction and psychological distress following early breast cancer treatment: a treatment decision support role for nurses Int J Nurs Pract 20 1 2014 8 16
63. A.L. McCarthy, P. Yates, and R.Z. Shaban Cross-sectional survey of the health behaviour of southeast Queensland women with cancer-treatment induced menopause: implications for cancer and primary care nurses Collegian 20 4 2013 223 231
64. C.D. Prouty, K.M. Mazor, and S.M. Greene Providers' perceptions of communication breakdowns in cancer care J Gen Intern Med 29 8 Aug 2014 1122 1130
65. G.V. Sørensen, P.A. Ganz, and S.W. Cole Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study J Clin Oncol 31 18 Jun. 20 2013 2265 2272
66. S. Holmes, E.J. Griffith, G. Musto, and G.Y. Minuk Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study Cancer Epidemiol 37 6 Dec. 2013 881 885
67. C. Chargari, J.B. Guy, and A.T. Falk Cardiotoxicity research in breast cancer patients: past and future Am J Cardiol 113 8 Apr. 15 2014 1447 1448
68. S. Khiati, I. Dalla Rosa, and C. Sourbier Mitochondrial topoisomerase I (Top1mt) is a novel limiting factor of doxorubicin cardiotoxicity Clin Cancer Res 20 18 Apr. 8 2014 4873 4881
69. D.J. Lenihan Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch? J Am Coll Cardiol 63 8 Mar. 4 2014 817 818
70. B. Ky, M. Putt, and H. Sawaya Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with Doxorubicin, taxanes, and trastuzumab J Am Coll Cardiol 63 8 Mar 4 2014 809 816
71. A. Abernethy, E. Abrahams, and A. Barker Turning the tide against cancer through sustained medical innovation: the pathway to progress Clin Cancer Res 20 5 Mar. 1 2014 1081 1086